| scholarly article | Q13442814 |
| P50 | author | Florian Herse | Q47804678 |
| Gerd Wallukat | Q63288594 | ||
| Ralf Dechend | Q63812628 | ||
| P2093 | author name string | Babbette LaMarca | |
| Joey P Granger | |||
| Mayte Llinas | |||
| P2860 | cites work | Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 |
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Activating auto-antibodies against the AT1 receptor in preeclampsia | Q36010629 | ||
| Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia | Q36288766 | ||
| Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia | Q36380482 | ||
| Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q43744800 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Endothelial dysfunction in preeclampsia | Q47879591 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986 | Q64128968 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoantibody | Q785022 |
| P304 | page(s) | 1168-1172 | |
| P577 | publication date | 2008-10-13 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats | |
| P478 | volume | 52 |
| Q54361188 | A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. |
| Q36115311 | A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q33983807 | Advances in the pathophysiology of pre-eclampsia and related podocyte injury |
| Q34978758 | Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q36339336 | An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia |
| Q37935034 | Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia |
| Q47799852 | Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy |
| Q35576417 | Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q37816496 | Animal models of pre-eclampsia. |
| Q46300987 | Animal models of preeclampsia: translational failings and why. |
| Q42796924 | Association Analysis about HLA-DRB1, -DQB1 Polymorphism and Auto-Antibodies Against α1-Adrenergic Receptors in Chinese Patients with Essential Hypertension |
| Q34473885 | Autoantibodies and cardiovascular dysfunction: cause or consequence? |
| Q28083815 | Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia |
| Q34508485 | CD4(+) T Cells Play a Critical Role in Mediating Hypertension in Response to Placental Ischemia |
| Q37699015 | Characterization of antibody specificities associated with preeclampsia |
| Q33799413 | Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy |
| Q36528002 | Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-α. |
| Q33607465 | Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy |
| Q36836373 | Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q36245112 | Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications |
| Q34772464 | Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance |
| Q37353537 | Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy |
| Q36073225 | Endothelin: key mediator of hypertension in preeclampsia |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q36115279 | Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system. |
| Q36244980 | Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q36409599 | Immune Mechanisms Linking Obesity and Preeclampsia |
| Q84984877 | Increased Myogenic Responses of Resistance-Sized Mesenteric Arteries After Reduced Uterine Perfusion Pressure in Pregnant Rats |
| Q36422496 | Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms |
| Q89860687 | Inflammasomes-A Molecular Link for Altered Immunoregulation and Inflammation Mediated Vascular Dysfunction in Preeclampsia |
| Q39198610 | Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase |
| Q49351706 | Inflammatory and Immune System Markers. |
| Q36050775 | Is preeclampsia an autoimmune disease? |
| Q36106483 | Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q46342648 | Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia |
| Q36910638 | Matrix metalloproteinases as drug targets in preeclampsia |
| Q37136212 | Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q58589187 | Molecular Determinants of Microvascular Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q27303128 | Neutrophil Depletion Attenuates Placental Ischemia-Induced Hypertension in the Rat |
| Q27010670 | New approaches for managing preeclampsia: clues from clinical and basic research |
| Q26865332 | Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology |
| Q92752365 | Perinatal Micro-Bleeds and Neuroinflammation in E19 Rat Fetuses Exposed to Utero-Placental Ischemia |
| Q36370720 | Placental ischemia impairs middle cerebral artery myogenic responses in the pregnant rat. |
| Q43744904 | Preeclampsia-associated stresses activate Gadd45a signaling and sFlt-1 in placental explants |
| Q64926884 | Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q37832764 | Preeclamptic nephropathy |
| Q28395340 | Pregnant rats treated with a high-fat/prooxidant Western diet with ANG II and TNF-α are resistant to elevations in blood pressure and renal oxidative stress |
| Q42701351 | Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor |
| Q36537709 | RAS in Pregnancy and Preeclampsia and Eclampsia |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q34429164 | Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q42356968 | Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy |
| Q33793455 | Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy |
| Q41653771 | Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat. |
| Q34785813 | Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia |
| Q37323529 | Sildenafil attenuates placental ischemia-induced hypertension |
| Q91910507 | The angiotensin II type I receptor contributes to impaired cerebral blood flow autoregulation caused by placental ischemia in pregnant rats |
| Q36407259 | The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy |
| Q38014802 | The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms |
| Q27003301 | The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? |
| Q57150158 | The role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q37336090 | Vasodilator factors in the systemic and local adaptations to pregnancy. |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
Search more.